Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

Yasuo Ohashi1 • Eiichi Shiba2 • Hiroko Yamashita3•4 • Junichi Kurebayashi5 • Shinzaburo Noguchi6 • Hirotaka Iwase7 • Michihiro Yoshida8 • Tsukasa Fujimoto8

Received: 16 May 2016 / Accepted: 2 October 2017 / Published online: 24 October 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Background We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years in premenopausal endocrine-responsive breast cancer patients and reported similar survival benefit in the two treatment groups. We hereby present patient-reported quality of life (QOL) data obtained from this trial.

Methods Three self-administered QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were used, and the difference in QOL score changes between the two groups was analyzed using a mixed-effects model for repeated measures. Results Eligible patients (N = 222) were randomly assigned to a 2-year (2YG, N = 112) or 3-or-more-year treatment group (3YG, N = 110). The time courses of the three QOL scores during the trial period were similar in the two groups. The mean changes in the QOL scores from week 96 were largely stable through week 240 in the 3YG, but showed significantly greater improvement in the score changes from week 96 in the 2YG than the 3YG. Symptoms associated with menopause such as hot flashes and sweating contributed to these results. Menstruation recovery was associated with significantly greater improvement of these symptoms in the 2YG than the 3YG.

Conclusions Patient-reported menopause-associated symptoms and QOL improved after discontinuation of the LH-RH agonist administration and menstruation recovery. QOL information should be a consideration in long-term treatment.

Keywords Premenopausal endocrine-responsive breast cancer • Adjuvant endocrine therapy • Leuprorelin acetate • Luteinizing hormone-releasing hormone agonist • Quality of life

Introduction

Recently, it is well recognized that patients’ physical and psychological well-being are as important as medical outcomes of
cancer treatment, especially among young women with breast cancer [1–7]. The assessment of quality of life (QOL) using self-administered questionnaires provides accurate insights into patients’ QOL status, such as physical and psychosocial well-being besides the impact of the cancer treatment itself, and offers invaluable information that is useful in decision-making processes concerning treatment options both for patients and clinicians [3–7]. For postoperative, premenopausal women with endocrine-responsive breast cancer, adjuvant endocrine therapy with more acceptable safety profiles and tolerability than adjuvant chemotherapy [8–10] is commonly used, indicating the potential efficacy of endocrine therapy to treat patients without compromising their QOL.

For the treatment of endocrine-responsive breast cancer in premenopausal women, it is of prime importance to suppress ovarian estrogen production through ovarian function suppression/ablation (OFS/OA). Currently, OFS with a luteinizing hormone-releasing hormone (LH-RH) agonist is widely used for 2 to 3 years as a postoperative adjuvant therapy in combination with tamoxifen for 5 years or chemotherapy in these patients [8–12]. A longer OFS with an LH-RH agonist for 5 years or longer is recommended for such patents at a high risk for recurrence [13]. At the St Gallen International Expert Consensus meetings, consensus was therefore reached on 5 years of tamoxifen alone or in combination with 5 years of an LH-RH agonist as the standard postoperative adjuvant therapy for premenopausal breast cancer patients [13–15].

Leuprorelin acetate (leuprorelin), an LH-RH agonist, is available as depot formulations (TAP-144-SR). It is commonly used worldwide for the treatment of hormone-responsive cancers, such as prostate cancer and premenopausal breast cancer. We recently conducted an open-label, randomized, controlled trial to evaluate the safety and efficacy of adjuvant therapy with TAP-144-SR (3M) administered every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen for 5 years in premenopausal women with endocrine-responsive breast cancer [16]. Adjuvant leuprorelin treatment for 3 or more years showed a similar survival benefit as treatment for 2 years, both in combination with tamoxifen, in premenopausal endocrine-responsive breast cancer patients. TAP-144-SR (3M) for 3 or more years was as well tolerated as TAP-144-SR (3M) for 2 years, and no new safety signals were identified for long-term TAP-144-SR (3M) treatment.

It is important to investigate patient-reported QOL in premenopausal breast cancer women receiving adjuvant hormone therapy, along with the acceptability of the treatment, which will provide a useful way of elucidating the risks and benefits of treatments [5, 6]. We therefore compared the effect of two adjuvant treatment regimens on patient-reported QOL during the 5-year treatment period in the above trial.

Patients and methods

Study design

This was an open-label, randomized, controlled trial of adjuvant therapy with TAP-144-SR (3M) administered every 3 months for 2 years versus 3 or more (up to 5) years in combination with tamoxifen given daily for 5 years to evaluate the optimal duration of treatment with TAP-144-SR (3M) in postoperative, premenopausal women with endocrine-responsive breast cancer [16]. We also compared the impact of two treatment regimens on patients’ QOL measured using three self-administered questionnaires during the 5-year treatment period in the above trial.

Patients and methods have previously been described in detail [16]. Briefly, eligible patients were randomly assigned at a 1:1 ratio to receive TAP-144-SR (3M) (11.25 mg) subcutaneous administration every 3 months either for 2 years or 3 or more (up to 5) years, in combination with tamoxifen (20 mg daily) given orally for 5 years. Random assignment was performed using dynamic allocation with the number of positive axillary lymph nodes (0, 1–3, ≥4), tumor diameter (≤2 cm, >2 cm), estrogen receptor (ER)/progesterone receptor (PgR) status (ER+/PgR+, ER+/PgR−, ER−/PgR−), age (at the time of enrollment; ≤39, 40–44, ≥45 years), pre- and postoperative chemotherapy (presence, absence), and study site.

Patients assigned to the 2-year treatment group (2YG) received TAP-144-SR (3M) for 2 years (96 weeks) and tamoxifen for 5 years (240 weeks). In the 3-or-more-year treatment group (3YG), patients who completed 3-year (144 weeks) TAP-144-SR (3M) treatment could extend that treatment for up to 5 years (240 weeks in total) if it was considered appropriate, while tamoxifen was administered throughout the 5-year trial period.

Patients

Patients were screened for eligibility according to the inclusion and exclusion criteria, which are described in the previous report [16]. Premenopausal patients with histologically confirmed primary breast cancer who met the following criteria were eligible for this trial: age ≥20 years; ER+ and/or PgR+ primary tumor; T1 to T3, any N, and M0, according to the TNM classification (Union for International Cancer Control, Sixth Edition, 2002); postoperative radiation of the breast in case of breast-conserving surgery; capable of receiving the trial drug and tamoxifen within 12 weeks after surgery or after postoperative adjuvant chemotherapy prior to enrollment; history of regular menstruation within 12 weeks prior to enrollment, or follicle-stimulating hormone (FSH) of <40 mIU/mL and estradiol (E₂) of ≥10 pg/mL as measured within 12 weeks prior to enrollment; not having a chemical menopause within 12 weeks after completion of postoperative
adjuvant chemotherapy; and performance status of grade 0 or 1.

Exclusion criteria included the following conditions or situations: endocrine therapy prior to surgery, postoperative adjuvant endocrine therapy before enrollment, bilateral oophorectomy and irradiation to bilateral ovaries, inflammatory breast cancer or bilateral breast cancer, and multiple cancers or a history of carcinoma in other organs.

Endpoints

As for QOL assessment, all participants were asked to fill out a self-administered QOL questionnaire form at randomization (baseline, week 0) and weeks 24, 48, 96, 144, 192, and 240. Changes in the QOL scores were measured using the following three questionnaires: (1) QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs (QOL-ACD) comprising 22 items regarding daily activity, physical condition, psychological condition, and social attitude [17]; (2) QOL-ACD-Breast (QOL-ACD-B) comprising 18 items regarding physical condition, pain, satisfaction with medical treatment, coping with the disease, adverse reactions by treatment, and others [18]; and (3) Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) subscale comprising 19 items related to endocrine therapy [19]. A 5-point scale was used for each item.

The menstruation status was investigated for 36 weeks after the completion of treatment with TAP-144-SR (3M), even after the trial period.

Statistical analysis

Since this trial was a pilot trial, the sample size was determined considering feasibility; that is, we planned to enroll 220 patients (110 per group) [16].

The statistical analyses were performed on patients in the full analysis set (FAS), which was defined as all patients receiving at least one dose of the trial drug after randomization or those in the modified FAS (mFAS), which was defined as patients included in the FAS who were examined at the end of the second year of treatment (week 96) and then continued treatment in the trial.

The time courses of QOL scores during the trial period were summarized as mean and SD at each time point in FAS. For analysis of the change in each QOL score and each subordinate item score from week 96 in the mFAS, the two groups were compared using a mixed-effects model for repeated measures at weeks 144, 192, and 240 using the score at week 0 as the covariate. Cohen’s d was calculated for week 0 and also for each visit as a standardized mean effect size of (2YG – 3YG)/(pooled SD) when the “group × visit interaction” or “difference between 2 groups in the main effect model” of repeated measures mixed model analysis was found to be significant. The Kaplan–Meier method was used to estimate the median menstruation recovery period from the last TAP-144-SR (3M) dosing. In addition, multiple regression analyses were applied to explore the relationships between the QOL subordinate item score changes and the patients’ condition, including their menopausal status.

The significance level of statistical testing was set at 0.05 except for 0.10 for group by visit interaction (two-sided). Statistical analyses were conducted using SAS (version 9.2).

Results

Patients

A total of 222 patients were enrolled and randomly assigned to receive TAP-144-SR (3M) for either the two YG (N = 112) or the three YG (N = 110). Of 222 patients in the FAS, 196 patients (99 and 97, in the 2YG and 3YG, respectively) completed the TAP-144-SR (3M) treatment, and 170 patients (81 and 89, respectively) completed the 5-year trial period. The median duration of the trial period was similar in the two treatment groups (1709 and 1711 days, respectively) [16].

Table 1 summarizes the baseline demographic and disease characteristics of patients in the FAS. The majority of patients had stage I (65.8%), lymph node-negative (89.2%), ER+/PR+ (93.2%) breast cancer and did not receive postoperative chemotherapy (89.6%). There were no significant differences in baseline characteristics between the groups except for serum E2 levels (Wilcoxon test, p = 0.033) [16].

The majority of patients in both treatment groups had good medication compliance with the trial treatment: 99 (88.4%) patients in the 2YG and 97 (88.2%) patients in the 3YG received 8 and 12 or more doses of TAP-144-SR (3M) specified in the protocol, respectively. Most patients (69.1%) in the 3YG received 20 doses, the maximum number of doses in the trial. Each group had good adherence to tamoxifen treatment throughout the 5-year trial period [16].

Quality of life

The time courses of QOL scores measured using the three questionnaires were similar between the two treatment groups during the trial period (Fig. 1, QOL-ACD; data not shown). The mean changes in the QOL scores from week 96 were largely stable throughout week 240 in the 3YG. Significantly greater improved score changes in the QOL-ACD-B score (total score of items 1 to 18) from week 96, however, were found in the 2YG than the 3YG (group × visit interaction, p = 0.017), especially at week 192 [mean difference, 3.4 points; Cohen’s d (effect size), 0.43; visit-wise between-group contrast test in repeated measures mixed-effects model, p = 0.003] and week 240 (3.0 points; 0.36; p = 0.010) as
shown in Fig. 2a. In addition, the mean changes in the FACT-ES subscale scores (except for the joint pain score (BRM1) based on the FACT-ES scoring guidelines version 4) from week 96 were significantly greater in the 2YG than the 3YG (group × visit interaction, \( p = 0.028 \)), especially at week 192 (2.5 points; 0.35; \( p = 0.008 \)) (Fig. 2b).

To identify a subordinate item that significantly affects each QOL score, the mean changes in the QOL-ACD-B and FACT-ES subordinate items scores from week 96 were analyzed using a repeated measures mixed-effects model. The following subordinate items were found to be significantly different between groups in mean score changes from week 96: the QOL-ACD-B subordinate item 1, “Did you have any pain or numbness in your breast, armpit or arm on the side of illness?”; item 2, “Did you have any bloating in your arm on the side of the illness?”; item 8, “Have you been satisfied with the facilities and staff, other than your doctor(s), at the hospital where you were diagnosed and/or treated?”; and item 13, “Were you bothered by hot flashes or sweating on your body or forehead?” (Table 2); FACT-ES subordinate item ES1, “I have hot flashes”; ES8, “I have pain or discomfort with intercourse”; and ES10, “I have gained weight” (Table 2). Especially, the subordinate items covering menopause-associated symptoms such as hot flashes and sweating showed a significant and relatively large effect size [QOL-ACD-B subordinate item 13 (Cohen’s \( d \), 0.34 at week 144, 0.71 at week 192, and 0.58 at week 240); FACT-ES subordinate item ES1 (0.92 at week 192 and 0.49 at week 240)]. As a result of stratified analysis by age (\( \leq 44 \) years, \( \geq 45 \) years) of these items as well as serum E2 levels and menstruation recovery, the effect size in the subpopulation aged \( \leq 44 \) years was 0.33, 0.87, and 0.71 (FACT-ES, ES1) at weeks 144, 192, and 240, respectively. However, in the subpopulation aged \( \geq 45 \) years, it was 0.38.

| Table 1 Baseline demographic and disease characteristics of patients | Overall (\( N = 222 \)) | Treatment group |
| --- | --- | --- | --- |
| | | 2 years (\( N = 112 \)) | 3 or more years (\( N = 110 \)) |
| Age (years) | Median (range) | 43.0 (25–56) | 43.5 (25–52) | 43.0 (27–56) |
| BMI (kg/m\(^2\)) | Mean (SD) | 21.8 (3.44) | 21.8 (3.29) | 21.8 (3.59) |
| Tumor stage (TNM classification) | | | | |
| I | 146 (65.8) | 74 (66.1) | 72 (65.5) |
| IIA | 60 (27.0) | 29 (25.9) | 31 (28.2) |
| IIB–IIIB | 16 (7.2) | 9 (8.0) | 7 (6.4) |
| Tumor size (cm) | | | | |
| \( \leq 2 \) | 165 (74.3) | 84 (75.0) | 81 (73.6) |
| \( > 2 \) | 57 (25.7) | 28 (25.0) | 29 (26.4) |
| Number of axillary lymph nodes | 0 | 198 (89.2) | 100 (89.3) | 98 (89.1) |
| 1–max | 24 (10.8) | 12 (10.7) | 12 (10.9) |
| ER/PgR status | | | | |
| ER+/PgR+ | 207 (93.2) | 103 (92.0) | 104 (94.5) |
| ER+/PgR− | 9 (4.1) | 5 (4.5) | 4 (3.6) |
| ER−/PgR+ | 6 (2.7) | 4 (3.6) | 2 (1.8) |
| Preoperative chemotherapy | | | | |
| Presence | 4 (1.8) | 2 (1.8) | 2 (1.8) |
| Absence | 218 (98.2) | 110 (98.2) | 108 (98.2) |
| Postoperative chemotherapy | | | | |
| Presence | 23 (10.4) | 12 (10.7) | 11 (10.0) |
| Absence | 199 (89.6) | 100 (89.3) | 99 (90.0) |
| Serum E2 (pg/mL) at week 0 | Median (interquartile range) | 90.5 (50.0–170.0) | 88.0 (37.0–144.0) | 101.5 (59.0–204.0) |

Values represent the number (%) of patients unless otherwise indicated

*BMI* body mass index, *ER* estrogen receptor, *PgR* progesterone receptor, *E2* estradiol
0.51, and 0.58 (QOL-ACD-B, item 13), and 0.16, 0.62, and 0.25 (FACT-ES, ES1), respectively (Table 2). The effect size was mostly greater in the subpopulation aged ≤ 44 years than in that aged ≥ 45 years at these time points.

**Serum E₂ level and menstruation recovery**

Serum E₂ levels significantly declined to menopausal levels (< 30 pg/mL) after 12 weeks of TAP-144-SR (3M) treatment and remained suppressed through the completion of administration in both groups. In the 2YG, serum E₂ levels gradually increased after the completion of TAP-144-SR (3M) treatment and recovered to almost the same levels as the pretreatment values by week 132 [16]. By stratifying the patient population by age of “≤ 44 years” and “≥ 45 years” at the randomization point, for the subpopulation aged ≤ 44 years in the 2YG, the proportion of patients with menstruation recovery was 51% (25/49), 85% (39/46), and 74% (32/43) at weeks 144, 192, and 240, respectively. In contrast, in the 3YG, the proportion of patients with menstruation recovery was much smaller: 0% (0/55), 6% (3/49), and 15% (7/47) at the respective time points. Although the proportion of patients with menstruation recovery among those aged ≥ 45 years in the 2YG was 24% (10/41), 33% (13/39), and 37% (14/38) at weeks 144, 192, and 240, respectively, no patients aged ≥ 45 years in the 3YG had menstruation recovery at any time points (Fig. 3a). The rate of menstruation recovery was higher in the subpopulation aged ≤ 44 years than ≥ 45 years at these time points. The median time from last TAP-144-SR (3M) dosing to first menstruation recovery by the Kaplan–Meier estimation was 430 and 1078 days for the subpopulations aged ≤ 44 and ≥ 45 years, respectively, in the 2YG, and
427 days and undeterminable for those aged ≤ 44 and ≥ 45 years, respectively, in the 3YG (Fig. 3b). The distribution of the recovery period was similar between the two groups for the subpopulation aged ≤ 44 years, although the number of patients with menses recovery was much smaller in the 3YG due to the shorter duration of the total menstruation follow-up period (trial period after the last dosing and follow-up observation period) than the 2YG.

**Relationship between QOL subordinate item score changes and patients’ status**

In order to explore the relationships between the QOL subordinate item score changes (QOL-ACD-B subordinate item 13 and FACT-ES subordinate item ES1) and patients’ status, including menopausal status, multiple regression analysis was performed using the mean score changes from week 96 in these subordinate items at weeks 144, 192, and 240 as dependent variables, and four factors [the treatment group, the age at the time of randomization (week 0), the corresponding QOL subordinate item scores at week 96, and the menstruation (presence/absence) at each assessment point] as independent variables. The results strongly suggested that in both QOL-ACD-B (item 13) and FACT-ES (ES 1), the QOL subordinate item at week 96 and the presence of menstruation at each assessment point had large standardized partial regression coefficients with change of corresponding QOL subordinate item scores at weeks 144, 192, and 240 (p < 0.001 for each) (Fig. 4).

**Discussion**

The primary objective of this open-label, randomized, controlled trial of TAP-144-SR (3M) administered every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen given daily for 5 years, was to investigate the appropriate treatment duration of LH-RH agonists in premenopausal women with endocrine-responsive breast cancer. In this trial, we also compared the effect of two treatment regimens on patient-reported QOL. The time courses of QOL scores measured using the three QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were similar between the two treatment groups (Fig. 1). The mean changes in the QOL scores from week 96 were largely stable through week 240 in the 3YG. However, significantly greater improvement in the score changes from week 96 was found in the 2YG than the 3YG: QOL-ACD-B score (total score of items 1 to 18) at weeks 192 and 240 and, FACT-ES subscale score (except the joint pain score) at week 192 (Fig. 2a), and FACT-ES subscale score (except the joint pain score) at week 192 (Fig. 2b).

The subordinate items indicating menopause-associated symptom burden such as hot flashes and sweating (i.e., QOL-ACD-B subordinate item 13 and FACT-ES subordinate item ES1) were shown to significantly improve in the 2YG compared to the 3YG in the mixed-effects model of repeated measures (Table 2). On the other hand, the exploratory multiple regression analysis indicated the great contribution of menstruation (presence/absence) at each time point and the corresponding QOL subordinate item scores at week 96 to
Table 2 QOL-ACD-B and FACT-ES subordinate items in repeated measures mixed model analyses and the stratification analyses

| Item                                                                 | Baseline | Repeated measures mixed model analysis<sup>b</sup> | Main effect model |
|----------------------------------------------------------------------|----------|---------------------------------------------------|-------------------|
|                                                                      | Group × visit interaction | Between-group comparison per visit<sup>c</sup> |                     |
|                                                                      | Group × visit interaction | Week 144 | Week 192 | Week 240 | Between the groups |
| 1. Did you have any pain or numbness in your breast, armpit or arm on the side of illness? | \( p = 0.567 \) \( (−0.08) \) | \( p = 0.040 \) | \( p = 0.007 \) | \( p = 0.096 \) |                     |
| 2. Did you have any bloating in your arm on the side of the illness? | \( p = 0.250 \) \( (−0.16) \) | \( p = 0.076 \) | \( p = 0.003 \) | \( p = 0.032 \) |                     |
| 3. Were you able to raise your arm completely on the side of the illness? | \( p = 0.095 \) \( (−0.24) \) | \( p = 0.581 \) | \( p = 0.978 \) | \( p = 0.848 \) |                     |
| 4. Did you worry about skin problems (redness, swelling, hot flashes, itchiness, etc.) at the area of your breast on the side of the illness? | \( p = 0.886 \) \( (0.02) \) | \( p = 0.189 \) | \( p = 0.040 \) | \( p = 0.164 \) |                     |
| 5. Did you have any pain associated with your illness or treatment? | \( p = 0.938 \) \( (−0.01) \) | \( p = 0.151 \) | \( p = 0.014 \) | \( p = 0.078 \) |                     |
| 6. (Answer this question only if you have had operations.) | \( p = 0.990 \) \( (0.00) \) | \( p = 0.438 \) | \( p = 0.243 \) | \( p = 0.669 \) |                     |
| Have you been satisfied with the appearance of your breast (and/or scar)? | \( p = 0.632 \) \( (0.07) \) | \( p = 0.883 \) | \( p = 0.429 \) | \( p = 0.764 \) | \( p = 0.442 \) |                     |
| 7. Have you been satisfied with the explanation you have received from your doctor(s) about your condition and/or treatment? | \( p = 0.216 \) \( (0.18) \) | \( p = 0.058 \) | \( p = 0.021 \) | \( p = 0.593 \) | \( p = 0.691 \) |                     |
| 8. Have you been satisfied with the facilities and staff, other than your doctor(s), at the hospital where you were diagnosed and/or treated? | \( p = 0.988 \) \( (0.00) \) | \( p = 0.405 \) | \( p = 0.224 \) | \( p = 0.997 \) | \( p = 0.547 \) |                     |
| 9. Do you feel that you have adequately accepted your illness? | \( p = 0.886 \) \( (0.02) \) | \( p = 0.189 \) | \( p = 0.040 \) | \( p = 0.164 \) |                     |
| Item | Baseline | Repeated measures mixed model analysis<sup>b</sup> | Main effect model |
|------|----------|------------------------------------------------|------------------|
|      |          | Group × visit interaction model | Between-group comparison per visit<sup>d</sup> | Between the groups |
|      |          | Group × visit interaction | Week 0<sup>c</sup> | Week 144 | Week 192 | Week 240 |
| 10. Have you been determined to fight your illness? | $p = 0.540$ | $p = 0.929$ | $p = 0.637$ | $p = 0.581$ | $p = 0.451$ | $p = 0.488$ |
| 12. Have you suffered from fatigue? | $p = 0.549$ | $p = 0.364$ | $p = 0.654$ | $p = 0.590$ | $p = 0.320$ | $p = 0.894$ |
| 13. Were you bothered by hot flashes or sweating on your body or forehead? | $p = 0.154$ | $p = 0.047$ | $p = 0.018$ | $p < 0.001$ | $p = 0.001$ | $p = 0.001$ |
| Age $\leq 44$ years | $p = 0.068$ | $p = 0.013$ | $p = 0.093$ | $p < 0.001$ | $p = 0.016$ | $p = 0.015$ |
| Age $\geq 45$ years | $p = 0.809$ | $p = 0.039$ | $p = 0.488$ | $p = 0.009$ | $p = 0.243$ | $p = 0.158$ |
| 18. Were you concerned that other members of your family would suffer from the same illness? | $p = 0.933$ | $p = 0.380$ | $p = 0.465$ | $p = 0.589$ | $p = 0.037$ | $p = 0.094$ |
| FACT-ES | | | | | | |
| ES1. I have hot flashes. | $p = 0.137$ | $p < 0.001$ | $p = 0.118$ | $p < 0.001$ | $p = 0.001$ | $p < 0.001$ |
| Age $\leq 44$ years | $p = 0.036$ | $p < 0.001$ | $p = 0.134$ | $p < 0.001$ | $p = 0.001$ | $p < 0.001$ |
| Age $\geq 45$ years | $p = 0.809$ | $p = 0.039$ | $p = 0.488$ | $p = 0.009$ | $p = 0.243$ | $p = 0.158$ |
| ES2. I have sweats. | $p = 0.842$ | $p = 0.196$ | $p = 0.222$ | $p = 0.017$ | $p = 0.092$ | $p = 0.089$ |
| ES3. I have night sweats. | $p = 0.234$ | $p = 0.391$ | $p = 0.886$ | $p = 0.302$ | $p = 0.324$ | $p = 0.568$ |
| ES4. I have vaginal discharge. | $p = 0.284$ | $p = 0.425$ | $p = 0.893$ | $p = 0.775$ | $p = 0.421$ | $p = 0.755$ |
| ES5. I have vaginal itching/irritation. | $p = 0.834$ | $p = 0.119$ | $p = 0.077$ | $p = 0.918$ | $p = 0.675$ | $p = 0.317$ |
| ES6. I have vaginal bleeding or spotting. | $p = 0.179$ | $p = 0.632$ | $p = 0.387$ | $p = 0.547$ | $p = 0.169$ | $p = 0.291$ |
| ES7. I have vaginal dryness. | $p = 0.099$ | $p = 0.988$ | $p = 0.654$ | $p = 0.582$ | $p = 0.647$ | $p = 0.574$ |
| ES8. I have pain or discomfort with intercourse. | $p = 0.537$ | $p = 0.919$ | $p = 0.051$ | $p = 0.048$ | $p = 0.033$ | $p = 0.016$ |
| Age $\leq 44$ years | $p = 0.675$ | $p = 0.744$ | $p = 0.190$ | $p = 0.129$ | $p = 0.061$ | $p = 0.068$ |
| Age $\geq 45$ years | $p = 0.660$ | $p = 0.992$ | $p = 0.118$ | $p = 0.190$ | $p = 0.211$ | $p = 0.088$ |
| ES9. I have lost interest in sex. | $p = 0.524$ | $p = 0.633$ | $p = 0.942$ | $p = 0.363$ | $p = 0.743$ | $p = 0.577$ |
the QOL improvement, and that there was no significant group difference after adjustment for these two factors (Fig. 4). The results could be interpreted as that the significant group difference of QOL improvement is almost explained by the recovery of menstruation after the completion of TAP-144-SR (3M) and some severity of hot flashes and sweating burden at week 96, and that the treatment group difference shows no significant additional impact on QOL improvement associated with any other unexplained factors.

In this trial, approximately 90% of patients in each group did not receive postoperative chemotherapy, which makes recovery of menstruation more likely. Menstruation recovery after completion of treatment was seen in more patients in the 2YG than the 3YG, particularly in the patient population aged ≤ 44 years in the 2YG at weeks 192 and 240 (Fig. 3a). Since the results of stratification by age of the above QOL subordinate items associated with hot flashes and sweating indicated greater improvement in the subpopulation aged...
Fig. 3 Menstruation and serum estradiol (E$_2$) levels at weeks 144, 192, and 240 in the 2-year and 3-or-more-year groups. a Menstruation and serum E$_2$ levels and b cumulative recovery rate. Period from last leuprolelin dosing to the first menstruation recovery was estimated by Kaplan–Meier method. $N$ number of patients evaluated, 144 w week 144, 192 w week 192, 240 w week 240
≤ 44 years in the 2YG at the same visits (Table 2), it also indicated that recovered menstruation after completion of treatment resulted in improvement of QOL concerning menopause-associated symptoms. The median time from last TAP-144-SR (3M) dosing to the first menstruation recovery by Kaplan–Meier estimation in the subpopulation aged ≤ 44 years was 430 days in the 2YG and 427 days in the 3YG (Fig. 3b), indicating that it took a similar number of days to recover menstruation in both groups. The above menstruation recovery results indicated that there were fewer patients with menstruation recovery in the 3YG than the 2YG during the 5 years (240 weeks). Such difference appears to be caused by the fact that a high proportion of patients in the 3YG received 20 doses of TAP-144-SR (3M), which is the maximum number of doses as specified in the protocol. Thus, the time to recover menstruation in the patient population aged ≤ 44 years was similar irrespective of the treatment duration. On the other hand, in the 3YG, there was only one patient with menstruation recovery during the follow-up observation in the patient population aged ≥ 45 years, and other patients with menstruation recovery in this patient population were in the 2YG. The median time from last TAP-144-SR (3M) dosing to the first menstruation recovery in the subpopulation aged ≥ 45 years by Kaplan–Meier estimation was 1078 days in the 2YG, indicating that it took a longer time to recover menstruation in comparison with the patient population aged ≤ 44 years (Fig. 3b).

Evaluation of menstruation recovery is thought to be more appropriate to interpret the time from last TAP-144-SR (3M) dosing to the first menstruation recovery than the proportion of patients with recovered menstruation at each visit because the treatment duration of TAP-144-SR (3M) was different among patients in the 3YG due to the trial design. In addition, unlike other study endpoints, the recovery of menstruation was continuously monitored for an additional 36 weeks after the completion of the last dosing. However, the length of the total menstruation follow-up period (trial period after the last dosing and follow-up observation period) in the 2YG was longer than that in the 3YG. Although the timing of recovery of menstruation after 5-year treatment in the patient population aged ≥ 45 years in the 3YG is presumed to coincide with the timing of natural menopause in some patients, it could be evaluated better by conducting further follow-up investigations.
Little is known about the impact of treatment on QOL in premenopausal breast cancer women receiving adjuvant hormone therapy; however, it is a major interest both for patients and clinicians [4]. A wide range of disease management based on QOL as well as other clinical presentation factors and individual patient conditions are necessary. In this study, the presence of menstruation contributed to provide significantly greater improvement in menopause-associated hot flashes and sweating burden in the 2YG than the 3YG. 3YG showed a little, but not statistically significant, survival benefit (regarding DFS and OS), and comparable safety profiles and tolerability compared with 2YG in premenopausal endocrine-responsive breast cancer patients, and no new safety signals were identified [16]. Recently, the TEXT and SOFT trials demonstrated that 5-year adjuvant treatment with an aromatase inhibitor, exemestane, plus OFS significantly reduced recurrence compared to tamoxifen plus OFS [20]. The results of the SOFT trial further showed that adding 5-year OFS with an LH-RH agonist to 5-year tamoxifen did not provide a significant overall DFS benefit in the study population, but it was beneficial in patients, especially young patients aged <35 years at a high risk for recurrence who needed adjuvant chemotherapy and remained premenopausal despite chemotherapy [21].

In view of the coverage of health insurance in Japan, we had no choice but to select the concomitant use of tamoxifen with OFS to evaluate the optimal treatment duration with TAP-144-SR (3M) in this trial. Given the results of the TEXT and SOFT trials, the addition of 5-year OFS with an LH-RH agonist to 5-year tamoxifen should be similarly recommended to premenopausal patients at a high risk for recurrence in Japan. This trial was a pilot trial and the sample size was not sufficient to fully understand patients’ QOL. Therefore, it should be further investigated in a larger population, but the use of TAP-144-SR (3M) for more than 2 years should be considered taking into account its potential impact on each patient’s QOL as well as the risk for recurrence.

This trial provides clinicians with beneficial information regarding QOL effects and menstruation recovery with long-term treatment of TAP-144-SR in premenopausal patients with endocrine-responsive breast cancer. This information is widely applicable to premenopausal patients administered TAP-144-SR.

Acknowledgements We are grateful to all the patients, investigators, and clinical research coordinators who participated in this trial. Takeda Pharmaceutical Company Limited sponsored this trial, collected and analyzed the trial data, and gave medical editorial assistance with this manuscript. The trial centers are as follows: Department of Breast Surgery, Hokkaido Cancer Center; Department of Surgery, Sapporo Breast Surgery Clinic; Breast Surgery, Fukushima Medical University Hospital; Department of Surgery, Hoshi General Hospital; Breast and Endocrine Surgery, Gunma University Hospital; Department of Breast Oncology, Gunma Prefectural Cancer Center; Division of Breast Surgery, Saitama Cancer Center; Breast Center, International University of Health and Welfare, Mita Hospital; Department of Breast Oncology, Juntendo University Hospital; Department of Breast and Endocrine Surgery, Tokai University Hospital; Department of Surgery, Yokohama Minami Kyoai Hospital; Department of Surgery, Shizuoka General Hospital; Department of Breast and Endocrine Surgery, Nagoya City University Hospital; Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases; Department of Breast and Endocrine Surgery, Osaka University Hospital; Department of Breast Surgery, Nakanoshima Osaka Breast Clinic; Department of Breast Surgery and Oncology, Hyogo Cancer Center; Department of Breast and Endocrine Surgery, Okayama University Hospital; and Department of Breast and Thyroid Surgery, Kawasaki Medical School. Editorial assistance in the preparation of this manuscript was provided by WysiWyg Co., Ltd., and financial support by Takeda Pharmaceutical Company Ltd.; the authors retained editorial control over the content.

Compliance with ethical standards

Conflict of interest Y. Ohashi received honoraria from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Shinogi Co., Ltd., and Daiichi-Sankyo Co., Ltd.; unspecified academic grants from Eisai Co., Ltd., and Yakult Honsha Co., Ltd.; and travel supports from Yakult Honsha Co., Ltd. and Takeda Pharmaceutical Co., Ltd., for international academic meetings; and is the chairman of the board of directors and owns stock of Statcom Co., Ltd. E. Shibata has nothing to disclose. H. Yamashita received research funding from Takeda Pharmaceutical Co., Ltd.; travel; and advisory fee from Takeda Pharmaceutical Co., Ltd. and research funding from Takeda Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., and AstraZeneca K.K. S. Noguchi received research funding from Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Pfizer Inc., Nippon Kayaku Co., Ltd., and Eisai Co., Ltd.; honoraria from Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Pfizer Inc., and Nippon Kayaku Co., Ltd.; and advisory fee from AstraZeneca K.K., Novartis Pharma K.K., and TAIHO Pharmaceutical Co., Ltd. H. Iwase received honoraria from AstraZeneca K.K., Novartis Pharma K.K., and Pfizer Inc.; and research funding from Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., TAIHO Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Daiichi Sankyo Co., Ltd. M. Yoshida is an employee of Takeda Pharmaceutical Co., Ltd., and received stock dividends from Takeda Pharmaceutical Co., Ltd. T. Fujimoto is an employee of Takeda Pharmaceutical Co., Ltd.

Ethical approval This trial was conducted in accordance with the International Conference on Harmonization of Good Clinical Practice Guidelines, the principles of the Declaration of Helsinki, and all applicable laws and regulations at 19 medical centers in Japan between June 2006 and March 2013. The protocol was reviewed and approved by the institutional review boards of all participating trial sites.

Informed consent All patients provided written informed consent for participation before enrollment in the trial. Written informed consent was also obtained from patients who completed the treatment with TAP-144-SR (3M) for 3 years in the 3YG and decided to extend the treatment.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Fallowfield LJ (1995) Assessment of quality of life in breast cancer. Acta Oncol 34:689–694
2. Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14:612–616
3. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer—taking stock. J Natl Cancer Inst 95:263–281
4. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Théberge V (2011) Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 103:178–231
5. Whelan TJ, Pritchard KI (2006) Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 12(3 Suppl):1056s–1060s
6. Perry S, Kowalski TL, Chang CH (2007) Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 5:24
7. Patterson RE, Saquib N, Natarajan L, Rock CL, Parker BA, Thomson CA, Pierce JP (2011) Improvement in self-reported physical health predicts longer survival among women with a history of breast cancer. Breast Cancer Res Treat 127:541–547
8. Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608
9. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namor M, Fogelman I, de Hae JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol 20:4628–4635
10. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
11. Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K (2007) Leuprolrelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 25:2509–2515
12. Klijn JGM, Blamey RW, Baccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of 4 randomized trials. J Clin Oncol 19:343–353
13. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel members (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206–2223
14. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329
15. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747
16. Shibata E, Yamashita H, Kurebayashi J, Noguchi S, Iwase H, Ohashi Y, Sassai K, Fujimoto T (2015) A randomized controlled study evaluating safety and efficacy of leuprolrelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer (2016) 23:499–509
17. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, Shimozuma K (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8:355–363
18. The Japanese Breast Cancer Society (2002) Guidelines for quality of life assessment studies of breast cancer patients, Version 1.0. (in Japanese)
19. Fallowfield LJ, Leatly SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189–199
20. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribó K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT and SOFT Investigators; International Breast Cancer Study Group (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107–118
21. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators; International Breast Cancer Study Group (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436–446